Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo – Andrea Morandi
š£ It’s OUT!
Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo! An exciting journey in collaboration withĀ Elisabetta Marangoni’s team at theĀ Institut CurieĀ joying our interest in therapy resistance and metabolic deregulation.
š¬ šØāš¬ A phenomenal effort of Elisabetta’s team with 14 PDX generated resembling the landscape of ER+ BC: from endocrine to CDK4/6i resistant models, to bone met metastasis matched to primary tumours. Patients’ derived material and functional data on isogenic cell models implemented the PDX data
1ļøā£ High expression of OXPHOS-related genes is associated with worse survival in breast cancer
2ļøā£ OXPHOS is a metabolic vulnerability in preclinical models of ER+ metastatic BC with endocrine and CDK4/6i resistance
3ļøā£ PIK3CA/AKT1 genes and MYC status predicts OXPHOS inhibitor response.
For article: Click here
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023